Neuphoria Therapeutics (NEUP) Return on Equity [ROE] (2024 - 2026)
Neuphoria Therapeutics (NEUP) posted Return on Equity [ROE] of -49.80% for fiscal Q4 2026 (quarter ended Jun 30, 2026), down 48.16 percentage points from -1.64% a year earlier but up 9.16 percentage points from the prior quarter.
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) Return on Equity [ROE] (2024 - 2026) Analysis & Trends
For FY2026 (ended Jun 30, 2026), Neuphoria Therapeutics' Return on Equity [ROE] came in at -61.70%, down 59.68 percentage points from FY2025.
- Annual Return on Equity [ROE] shows a five-year change of -32.05 percentage points (FY2021 to FY2026).
- In prior fiscal years, Neuphoria Therapeutics' Return on Equity [ROE] was -2.03% in FY2025 (+76.41 pp), -78.44% in FY2024 (-10.63 pp), -67.81% in FY2023 (-27.55 pp) and -40.26% in FY2022 (-10.61 pp).
- Quarterly Return on Equity [ROE] has run from a low of -87.44% in fiscal Q4 2024 to a high of 29.32% in fiscal Q3 2025 over five years.
- On a year-over-year basis, Return on Equity [ROE] increased in three of the last five quarters, with an average year-over-year change of -4.33 percentage points.
- According to Business Quant data, Return on Equity [ROE] for the three prior fiscal quarters was -58.96% (Q3 2026), -26.84% (Q2 2026) and -60.11% (Q1 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 25.32% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 7.21% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 84.40% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 21.39% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 83.75% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -18.38% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 4.97% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 22.24% |
| 10 | Neuphoria Therapeutics | 443.79 Mn | 368.60 Mn | - | -49.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.80% |
| Mar 31, 2026 | -58.96% |
| Dec 31, 2025 | -26.84% |
| Sep 30, 2025 | -60.11% |
| Jun 30, 2025 | -1.64% |
| Mar 31, 2025 | 29.32% |
| Dec 31, 2024 | -53.30% |
| Sep 30, 2024 | -62.64% |
| Jun 30, 2024 | -87.44% |
API Access
Neuphoria Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NEUP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "NEUP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NEUP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();